Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

BACKGROUND: We investigated real-world effectiveness and safety of sofosbuvir and the nonstructural protein 5A inhibitors in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6. METHODS: We analyzed data from 1021 patients with HCV infection (506 with genotype...

Descripción completa

Detalles Bibliográficos
Autores principales: Charatcharoenwitthaya, Phunchai, Wongpaitoon, Virasak, Komolmit, Piyawat, Sukeepaisarnjaroen, Wattana, Tangkijvanich, Pisit, Piratvisuth, Teerha, Sanpajit, Theeranun, Sutthivana, Chinnavat, Bunchorntavakul, Chalermrat, Sobhonslidsuk, Abhasnee, Chonprasertsuk, Soonthorn, Siripipattanamongkol, Chotipong, Sethasine, Supatsri, Tanwandee, Tawesak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057522/
https://www.ncbi.nlm.nih.gov/pubmed/32138687
http://dx.doi.org/10.1186/s12876-020-01196-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057522/
https://www.ncbi.nlm.nih.gov/pubmed/32138687
http://dx.doi.org/10.1186/s12876-020-01196-0

Ejemplares similares